4-((4-(4-Chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)-oxy)-6-(dimethylamino)-1-methylpyrimidin-2(1H)-one

ID: ALA3792717

Chembl Id: CHEMBL3792717

PubChem CID: 121448460

Max Phase: Preclinical

Molecular Formula: C21H17ClF5N3O3

Molecular Weight: 489.83

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CN(C)c1cc(OCc2cc(F)c(Oc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)nc(=O)n1C

Standard InChI:  InChI=1S/C21H17ClF5N3O3/c1-29(2)18-9-17(28-20(31)30(18)3)32-10-11-6-15(23)19(16(24)7-11)33-12-4-5-14(22)13(8-12)21(25,26)27/h4-9H,10H2,1-3H3

Standard InChI Key:  RUTJDPQPSRQBEG-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3792717

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver (4264 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 489.83Molecular Weight (Monoisotopic): 489.0879AlogP: 5.17#Rotatable Bonds: 6
Polar Surface Area: 56.59Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 0.86CX LogP: 5.16CX LogD: 5.16
Aromatic Rings: 3Heavy Atoms: 33QED Weighted: 0.45Np Likeness Score: -1.16

References

1. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J..  (2016)  Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,  59  (6): [PMID:26927682] [10.1021/acs.jmedchem.5b01930]

Source